Compare LFUS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | PODD |
|---|---|---|
| Founded | 1927 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.3B |
| IPO Year | 1996 | 2007 |
| Metric | LFUS | PODD |
|---|---|---|
| Price | $417.64 | $147.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $366.67 | $341.48 |
| AVG Volume (30 Days) | 182.3K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.96 | 2.67 |
| Revenue | $757,853,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $14.65 | $24.55 |
| Revenue Next Year | $6.98 | $19.18 |
| P/E Ratio | $139.62 | ★ $56.08 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $233.36 | $126.40 |
| 52 Week High | $500.57 | $354.88 |
| Indicator | LFUS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 50.87 |
| Support Level | $386.67 | $139.67 |
| Resistance Level | $426.44 | $155.17 |
| Average True Range (ATR) | 15.42 | 5.28 |
| MACD | -1.89 | 0.94 |
| Stochastic Oscillator | 20.52 | 67.83 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.